At a public hearing yesterday at the Dept. of Health, doctors, dentists, physician assistants, and advanced practice nurses voiced their opposition to the department's proposed regulations governing the prescribing of opioids. The new rules would require prescribers to sign a fairly lengthy agreement with patients, alerting them to the risks of taking prescription painkillers like OxyContin and Vicodin, and agreeing to certain kinds of monitoring. Many health care providers feel these agreements aren't necessary and that, in fact, they're patronizing.
No surprise here: the Philadelphia Transportation Authority is suing Gilead, maker of the expensive new hepatitis C drugs Sovaldi and Harvoni, over the cost of those drugs. A course of Sovaldi, not including drugs you might have to take in combination with it, as some patients do, costs $84,000. Harvoni, which won FDA approval more recently, costs $94,000.
A Rhode Island doctor has just returned from Liberia where for three months he trained health care workers fighting the deadly Ebola virus. Dr. Timothy Flanigan is one of several Rhode Islanders who have traveled to the West African nation to fight the disease that the World Health Organization estimates to have killed some 6500 people.
Shortly after arriving back home, he sat down with me to talk about what he saw and where he sees hope.
Sen. Sheldon Whitehouse says he hopes legislation to boost funding to treat addiction will move forward this week. Whitehouse and colleagues from both sides of the aisle hosted addiction experts on Capitol Hill this morning to learn more about the challenges that remain for addicts even in recovery.
For the past several weeks we've been airing stories from our series, "At the Crossroads: The rise of hepatitis C and the fight to stop it." Maybe you've been wondering, hey, should I get tested? Where can I do that? And what's it like?
Wonder no more. Here's a collection of resources to get you started.
My recent story about the high cost of new hepatitis C treatments focused on the difficulty of deciding who gets these new drugs now and who has to wait. That's because, while new drugs like Sovaldi and Harvoni (both made by Gilead) promise to cure a lot of people, they're so expensive we simply couldn't afford to treat everyone who's infected right now.
HealthSource RI director Christine Ferguson has penned an op-ed in the Providence Journal to plead her case for keeping the health insurance exchange in local hands. Her commentary comes days after a Projo editorial arguing the state should scrap its exchange.